key: cord-0774111-raop7odt
authors: Tandon, R.; Mitra, D.; Sharma, P.; Stray, S. J.; Bates, J. T.; Marshall, G. D.
title: Effective Screening of SARS-CoV-2 Neutralizing Antibodies in Patient Serum using Lentivirus Particles Pseudotyped with SARS-CoV-2 Spike Glycoprotein
date: 2020-05-23
journal: nan
DOI: 10.1101/2020.05.21.20108951
sha: 776a6848707f4ef688c46f9faed5d94a72e28006
doc_id: 774111
cord_uid: raop7odt

Pseuodotyped particles have significant importance and use in virology as tools for studying the biology of highly pathogenic viruses in a lower biosafety environment. The biological, chemical, and serological studies of the recently emerged SARS-CoV-2 will be greatly aided by the development and optimization of a suitable pseudotyping system. Here, we pseudotyped the SARS-CoV-2 Spike glycoprotein (SPG) on a retroviral (MMLV) as well as a third generation lentiviral (pLV) vector and tested the transduction efficiency in several mammalian cell lines expressing SARS-CoV-2 receptor hACE2. While MMLV pseudotyped the vesicular stomatitis virus G glycoprotein (VSV-G) efficiently, it could not pseudotype SPG. In contrast, pLV pseudotyped both glycoproteins efficiently; however, much higher titers of pLV-G particles were produced. Among all the tested mammalian cells, 293Ts expressing hACE2 were most efficiently transduced using the pLV-S system. The pLV-S particles were efficiently neutralized by diluted serum (>:640) from a recently recovered COVID-19 patient who showed high SARS-CoV-2 specific IgM and IgG levels. In summary, pLV-S pseudotyped virus provides a valid screening tool for the presence of anti SARS-CoV-2 specific neutralizing antibodies in convalescent patient serum.

The recent emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) in Wuhan, China in late 2019 and its subsequent spread to the rest of the world has created a pandemic situation unprecedented in modern history (1) (2) (3) (4) . While initial challenges included diagnosis and proper containment of the infection, contemporary efforts are directed towards the measurement of antiviral total and neutralizing antibodies in recovered and symptomatic patients as well as in non-symptomatic vulnerable population (5) (6) (7) . Studying the development of herd immunity, effectiveness of various upcoming vaccine candidates as well as establishing social parameters for re-opening of the world economy all depend on our ability to accurately measure neutralizing antibodies and establish the kinetics of their persistence in serum.

Convalescent plasma therapy has shown early therapeutic successes in severe COVID-19 patients (8) . Thus, the determination of neutralizing antibody titers in convalescent serum should provide significant assistance in clinical decision making regarding transfusion for therapeutic and possibly prophylactic indications.

Due to the highly transmissible and pathogenic nature of SARS-CoV-2, handling of live virus requires a biosafety level 3 (BSL3) containment (9). Thus, only facilities equipped with BSL-3 can safely study neutralizing responses using live virus. In order to extend this capability to other BSL-2 laboratories that are more widely available, a safer way is needed to measure both total antiviral antibody levels based on ELISAs and neutralizing antibody responses in a practical, reproducible surrogate assay that effectively replaces the need for the live SARS-CoV-2. To address this issue, we report the development of a high titer pseudotype virus that can be easily produced and successfully employed to screen patient serum for neutralizing antibodies in a lower biosafety level laboratory.

Since the backbone of this virus consists of a non-replicating lentivirus, it poses no risk of infection to the personnel involved and the technology can readily be scaled up to the levels where it can be employed for screening of large sample numbers. These pseudotyped particles (pLV-S) can also be used for immunological, pharmacological and biochemical studies as it represents SPG in its native conformation. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20108951 doi: medRxiv preprint

We used a traditional retroviral pseudotyping system based on Murine Molony Leukemic Virus (MMLV) vector (10, 11) and a lentiviral vector (pLV) (12, 13) in parallel to compare the pseudotyping efficiencies in these two related but different systems. The pLV vector pseudotyped both VSV-G (pLV-G) and SARS-CoV-2 spike glycoprotein (pLV-S) efficiently, whereas MMLV vector could only pseudotype VSV-G (Fig 1) . The success of pseudotyping was assessed by the expression of green fluorescent protein (gfp) since both MMLV and pLV vectors integrate the gene encoding for gfp.

We compared the efficiency of pLV-S transduction in 293T and VeroE6 cells since both of these cells are known to express the putative S receptor hACE2 on their surface in sufficient quantities to allow for virus entry (14) . The 293T cells were transduced much more efficiently with pLV-G than pLV-S, whereas Vero E6 cells showed a low level of transduction for both viruses (Fig 2) . We then analyzed the transduction efficiencies of adenocarcinomic human alveolar basal epithelial cells (A549), Madin-Darby Canine Kidney (MDCK), Vero E6 and 293T cells and compared them to 293T cells transfected with plasmid encoding hACE2 receptor. While untransfected 293T cells were half as efficient as hACE2 transfected cells, the MDCK, VeroE6 and A549 showed only a low level of transduction (Fig 2) . Thus, the 293T cell line was used in the development of the neutralizing antibody assay.

We tested the impact of patient serum on pLV-S transduction. Serial dilutions (1:40, All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20108951 doi: medRxiv preprint 1:80, 1:160: 1:320, 1:640 and 1:1280) of serum were made in the serum-free cell culture medium and incubated with equal amounts of pLV-S virus, then plated on 293T cells. Fluorescence images captured at 48 hours post infection showed significant reduction in pLV transduction with the serum from patient N304 but not from N308 (Fig.   3 ). Patient N304 tested positive in a RT-PCR assay for SARS-CoV-2, suffered a severe COVID-19 pneumonia and eventually recovered. Patient N308 suffered mild symptoms consistent with an upper respiratory infection but tested negative for SARS-CoV-2 infection by RT-PCR.

Here we report the development of a lentiviral pseudotyping system for SARS-CoV-2 and its efficacy in detecting neutralizing antibody titers in convalescent patient serum.

While a few pseudotyping systems for SARS-CoV-2 are in development, this report provides initial evidence that lentiviral pseudotyped SARS-CoV-2 can be used to determine neutralizing antibody titers in patient samples.

We first tried a traditional retroviral pseudotyping system based on MMLV. We have used this system earlier for creating cell lines stably expressing viral proteins of interest (15, 16) . While the control VSV-G protein was pseudotyped successfully, we could not pseudotype SARS-CoV-2 SPG onto this backbone. Since retroviral vectors require actively dividing cells for successful transduction, we tested 293T cells at different levels of confluency but were unable to transduce them. The relative efficiency of VSV-G to transduce similar cells indicate that inherent qualities or complexity of SPG structure may make it more difficult to pseudotype it in this system.

Next, we utilized a third generation lentiviral system to pseudotype VSV-G and SPG.

This system was able to pseudotype both glycoproteins although, as expected, efficiency was much better for VSV-G. The transduction efficiency would logically be guided by the level of SPG receptor expression on cells, therefore, we tested various mammalian cells lines that were available to us and are known express hACE2. We All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20108951 doi: medRxiv preprint also transfected cells (293Ts) with hACE2 plasmid and compared transduction efficiency of different cells to these hACE2-293T. None of the cells transduced as efficiently as hACE2-293Ts and mock transfected 293Ts were only 42% efficient (Fig 2) .

Since the differences between hACE2-293Ts and 293Ts were only 2-2.4 fold, we decided to use 293Ts for patient serum screening.

Serum samples were obtained from two patients at University of Mississippi Medical

Center. The first patient (N304) tested positive for SARS-CoV-2 in a RT-PCR assay and was convalescent at the time of sample collection. The second patient (N308) was mildly symptomatic and tested negative for SARS-CoV-2 (N308) in the same RT-PCR assay. Both serums were collected thirty days after onset of symptoms while patients were totally asymptomatic. Antibody testing in a SARS-CoV-2 SPG receptor binding domain ELISA revealed higher levels of RBD-specific IgM and RBD-specific IgG for N304 but lower levels for N308 (Table 1) . Serial dilutions of serum N304 effectively neutralized pLV-S up to 1:1280 dilution whereas N308 did not neutralize the virus at higher than 1:80 dilution (Fig 3) .

Thus, the pseudotyped virus (pLV-S) can be effectively used for screening of patient serum for the presence of neutralizing antibodies associated with acquired immunity to subsequent infection upon re-exposure. Determining functional immunity has potential social implications as the world community begins to recover from the tremendous social impact of the pandemic. Information regarding the development of herd immunity is important in this effort and can be gained from the results of this assay as well. These pseudoparticles can also be utilized for screening of inhibitors of SPG-hACE2 binding and resultant virus entry. They can also be utilized for screening of potential vaccine candidates as they represent SPG on their surface in its native confirmation.

Cells: 293T (ATCC # CRL3216), Vero E6 (ATCC # CRL1586) and MDCK (ATCC #CCL-34) were cultured in DMEM (Corning Inc) supplemented with 10% fetal bovine All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20108951 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20108951 doi: medRxiv preprint

China Novel Coronavirus I, Research T. 2020. A Novel Coronavirus from Patients with Pneumonia in China

A new coronavirus associated with human respiratory disease in China

Another Decade, Another Coronavirus

Responding to Covid-19 -A Once-in-a-Century Pandemic?

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

A human monoclonal antibody blocking SARS-CoV-2 infection

Rapid development of an inactivated vaccine candidate for SARS-CoV-2

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Improved retroviral vectors for gene transfer and expression

Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line

A third-generation lentivirus vector with a conditional packaging system

Generation of HIV-1 derived lentiviral vectors

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Control of cytoplasmic maturation events by cytomegalovirus tegument protein pp150

Human Cytomegalovirus pUL93 Is Required for Viral Genome Cleavage and Packaging

SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

We would like to acknowledge the receipt of pCAGG-S and pCAGGS-RBD plasmids from Florian Krammer at Icahn School of Medicine at Mount Sinai Hospital, NY. Funding for this work was provided by University of Mississippi Medical Center COVID-19 funds. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted May 23, 2020.

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted May 23, 2020. . https://doi.org/10.1101/2020.05.21.20108951 doi: medRxiv preprint